Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07465224 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
A Phase 2 study of Type 2 Diabetes Mellitus (T2DM), sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07465224: Recruiting Phase 2 study of Type 2 Diabetes Mellitus (T2DM), sponsored by Alnylam Pharmaceuticals.
NCT07465224 is a Phase 2 study of Type 2 Diabetes Mellitus (T2DM) that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 40 participants, below the 520-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07465224, a Phase 2 study of Type 2 Diabetes Mellitus (T2DM), is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
Primary Outcome
M-value is measured as the glucose infusion rate at steady state
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALN-4324
Study Locations (1)
California
- Clinical Trial Site - Chula Vista
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2027-05-28 |
| Phase | Phase 2 |
What NCT07465224 shows while recruiting
NCT07465224 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 520-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus (T2DM) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07465224 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07465224 about?
NCT07465224 is a clinical study titled "A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
What is the current status of trial NCT07465224?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2026-01-15. Estimated completion is 2027-05-28.
What conditions does trial NCT07465224 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus (T2DM).
What interventions are being tested in trial NCT07465224?
The interventions under investigation include: Placebo (DRUG), ALN-4324 (DRUG).
Who is sponsoring clinical trial NCT07465224?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07465224 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus (T2DM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07465224's enrollment target sits among peer trials
40 20th of 24 higher than 3 of 24 other Type 2 Diabetes Mellitus (T2DM) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus (T2DM) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
ACTIVE NOT RECRUITING · Phase 2
-
A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
ACTIVE NOT RECRUITING · Phase 2
-
Preventing Medication Mismanagement in People Living with Dementia Through Automated Medication Dispensing with Facial Recognition and Video Observation
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI